What is Organogenesis Holdings Inc.'s market cap?

Organogenesis Holdings Inc. (ORGO) has a market capitalization of $328.1M and trades on NASDAQ.

What is Organogenesis Holdings Inc.'s revenue and profitability?

Organogenesis Holdings Inc. generated $514.7M in trailing twelve-month revenue with net income of $2.7M, representing a net margin of 0.5%. Gross margin stands at 75.9%, with free cash flow of -$34.5M. These figures are based on the Q1 2026 filing.

Who are Organogenesis Holdings Inc.'s competitors?

Organogenesis Holdings Inc.'s key competitors include MiMedx Group, Integra LifeSciences, SANUWAVE Health, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Organogenesis Holdings Inc. partner with?

Organogenesis Holdings Inc.'s notable partners include Novartis Pharma AG, RESORBA Medical GmbH, DIV Technology Way, LLC.

What subsidiaries does Organogenesis Holdings Inc. have?

Organogenesis Holdings Inc.'s subsidiaries include NuTech Medical.

Where is Organogenesis Holdings Inc. headquartered?

Organogenesis Holdings Inc. is headquartered in United States of America and employs approximately 862 people. It has been publicly traded since 2016.

Organogenesis Holdings Inc.

ORGO

Organogenesis is a leading regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care and surgical and sports medicine markets.

Market cap

$328.12M-44.5%

Revenue$514.7M+12.2%

Net income$2.7M+117%

Free cash flow-$34.5M-67.6%

EPS (diluted)-$0.16+30.4%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$36.3MMiss by $7.0M EPS-$0.37Miss by $0.08

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$54.3M

EPS estimate-$0.35

Financials

Q1 2026

Income statement

See full

Revenue$37.2M-57.1%

Operating income-$68.9M-158%

Net income-$53.2M-182%

EPS (diluted)-$0.44-159%

Balance sheet

See full

Cash & equivalents$91.4M-16.9%

Total debt$39.4M+24.8%

Total equity$244.6M+0.7%

Total assets$520.0M+11.3%

Cash flow

See full

Operating cash flow$21.1M+206%

CapEx$3.1M-13.2%

Free cash flow$18.0M+176%

Valuation & ratios

Valuation

See full

Market cap$328.12M-44.5%

Enterprise value$276.16M-53.5%

P/E120.7×—

P/S0.6×-0.8×

Profitability

See full

Operating margin0.5%—

Net margin0.5%+0.3pp

Returns & leverage

See full

Return on equity1.1%+0.6pp

Debt / equity0.2×0.0×

Current ratio3.5×-0.6×

Segments

By product

See full

Grant$978.0K—

Competitors

By market cap

Solventum$13.9B+9.2%

Axogen$2.2B+270%

IAR

Integra LifeSciences$1.5B+49.2%

MiMedx Group$634.5M-36.7%

Organogenesis Holdings Inc.$328.1M-48.5%

SANUWAVE Health, Inc.$52.5M—

Celularity$21.7M-72.4%

Pluri Inc.$17.7M-58.2%

By revenue growth

SANUWAVE Health, Inc.+22.5%

Axogen+22.4%

Organogenesis Holdings Inc.+12.2%

MiMedx Group+10.5%

IAR

Integra LifeSciences+1.6%

Solventum-0.5%

By net margin

SANUWAVE Health, Inc.37.2%+132pp

Solventum17.33%+12.8pp

MiMedx Group7.88%-3.5pp

Organogenesis Holdings Inc.0.528%+4.0pp

IAR

Integra LifeSciences-0.44%+32.4pp

Axogen-13.21%-9.3pp

Profile

Organogenesis is a leading regenerative medicine company that develops, manufactures, and commercializes solutions for the advanced wound care and surgical and sports medicine markets. The company leverages a diverse portfolio of bioengineered cultured cellular products and placental-based tissues to promote healing in chronic and acute wounds. Its core value proposition centers on providing clinically proven, regenerative technologies that address complex medical conditions like diabetic foot ulcers and musculoskeletal injuries.

Competitive position

A leading player in the skin substitute market with a unique portfolio containing both PMA-approved and 510(k)-cleared products alongside 361 HCT/Ps.

GeographiesUnited States, Switzerland, Saudi Arabia, Kuwait

Customer segmentsHealthcare providers, Surgical centers, Specialty clinics

Business modelManufacturing, Direct sales, Research and development

SuppliersDonated human tissue, Porcine tissue suppliers, Bovine tissue suppliers, Contract manufacturers, Raw material suppliers

CustomersHospitals, Wound care centers, Ambulatory surgery centers, Physician offices, Group Purchasing Organizations (GPOs)

CountryUnited States of America

Listed2016

Employees862.0

CEOGary S. Gillheeney

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

Websiteorganogenesis.com

FilingsSEC EDGAR

Ask your AI about Organogenesis Holdings Inc..

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Organogenesis Holdings Inc.'s market cap?: Organogenesis Holdings Inc. (ORGO) has a market capitalization of $328.1M and trades on NASDAQ.
What is Organogenesis Holdings Inc.'s revenue and profitability?: Organogenesis Holdings Inc. generated $514.7M in trailing twelve-month revenue with net income of $2.7M, representing a net margin of 0.5%. Gross margin stands at 75.9%, with free cash flow of -$34.5M. These figures are based on the Q1 2026 filing.
Who are Organogenesis Holdings Inc.'s competitors?: Organogenesis Holdings Inc.'s key competitors include MiMedx Group, Integra LifeSciences, SANUWAVE Health, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Organogenesis Holdings Inc. partner with?: Organogenesis Holdings Inc.'s notable partners include Novartis Pharma AG, RESORBA Medical GmbH, DIV Technology Way, LLC.
What subsidiaries does Organogenesis Holdings Inc. have?: Organogenesis Holdings Inc.'s subsidiaries include NuTech Medical.
Where is Organogenesis Holdings Inc. headquartered?: Organogenesis Holdings Inc. is headquartered in United States of America and employs approximately 862 people. It has been publicly traded since 2016.